发明名称 Combination treatments for chemokine-mediated diseases
摘要 A use of one or more compounds of formula (I) or a pharmaceutical acceptable salt or solvate thereof, in combination with other classes of pharmaceutical compounds; for the manufacture of one or more medicaments for treating a CXC chemokine mediated disease is disclosed, wherein the variables shown in formula (I) are as defined in the specification. These compounds of formula (I) in combination with other classes of pharmaceutical compounds are particularly suitable for treating chemokine-mediated diseases such as acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma, cancer and many other diseases as disclosed in the specification.
申请公布号 NZ535314(A) 申请公布日期 2007.08.31
申请号 NZ20030535314 申请日期 2003.03.17
申请人 SCHERING CORPORATION 发明人 TAVERAS, ARTHUR G;BILLAH, MOTASIM;LUNDELL, DANIEL;KREUTNER, WILLIAM;JAKWAY, JAMES;FINE, JAY S;BOBER, LORETTA A;CHAO, JIANHUA;BIJU, PURAKKATTLE;YU, YOUNONG
分类号 C07D295/18;A61K31/166;A61K31/167;A61K31/277;A61K31/341;A61K31/351;A61K31/36;A61K31/381;A61K31/397;A61K31/40;A61K31/401;A61K31/415;A61K31/422;A61K31/427;A61K31/4412;A61K31/4422;A61K31/443;A61K31/455;A61K31/495;A61K31/496;A61K31/505;A61K31/506;A61K31/53;A61K31/5375;A61K45/00;A61K45/06;A61P1/00;A61P1/02;A61P1/04;A61P1/16;A61P1/18;A61P3/00;A61P7/00;A61P7/02;A61P9/00;A61P9/10;A61P11/00;A61P11/02;A61P11/06;A61P11/08;A61P13/12;A61P15/00;A61P17/00;A61P17/02;A61P17/06;A61P19/00;A61P19/02;A61P19/06;A61P19/10;A61P21/00;A61P25/00;A61P25/02;A61P25/28;A61P27/00;A61P27/02;A61P29/00;A61P31/04;A61P31/12;A61P31/16;A61P31/18;A61P33/06;A61P35/00;A61P37/06;A61P37/08;C07D205/04;C07D207/08;C07D207/12;C07D207/333;C07D213/74;C07D213/81;C07D213/82;C07D213/89;C07D231/38;C07D239/42;C07D239/47;C07D241/04;C07D307/52;C07D307/68;C07D309/14;C07D317/58;C07D333/20;C07D333/38;C07D405/06;C07D405/12;C07D409/12;C07D413/12;C07D413/14;(IPC1-7):A61K31/422;A61K31/440;A61K31/416;A61K31/426 主分类号 C07D295/18
代理机构 代理人
主权项
地址